Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its ...

Pharmaceutical giant AbbVie has sued cancer treatment maker BeiGene in Chicago federal court, accusing it of stealing trade ...

New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and ...

The Irish drug maker Shire is paying a premium for NPS Pharmaceuticals, which is based in New Jersey, as part of its effort to recover from its botched sale to AbbVie last year. The agreement ...

Just a few short weeks after winning an FDA Fast Track tag for its investigational BTK degrader in certain blood cancers, ...

AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

A recent global study raises questions about the effectiveness of costly, modern migraine medications, revealing that they ...